BioSpace News Archive

Initial results from the TROPION-Lung04 phase 1b trial showed that datopotamab deruxtecan in combination with durvalumab, an anti-PD-L1 therapy, with or without carboplatin demonstrated encouraging responses and no new safety signals in patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Crinetics Pharmaceuticals, Inc. announced that paltusotine, an oral, once-daily investigational compound, achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study.

Allist Pharmaceuticals Co., Ltd. and ArriVent Biopharma, Inc. together announced that interim results from the Phase Ib, randomized, open-label, multi-center clinical study, evaluating the efficacy and safety of furmonertinib in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.

Mineralys Therapeutics, Inc. presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension and resistant hypertension.

Amgen announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer.

Results from the HERTHENA-Lung01 phase 2 trial showed that patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer following disease progression with an EGFR TKI and platinum-based chemotherapy.

Gilead Sciences, Inc. announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Mineralys Therapeutics, Inc. announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension and treatment-resistant hypertension were published in the Journal of the American Medical Association.